Alnylam Pharmaceuticals, INC. (ALNY) — 10-Q Filings

10-Q Filings (6)

• Alnylam Swings to Profit on Soaring Product & Collaboration Revenue — Oct 30, 2025 Risk: medium
  Alnylam Pharmaceuticals, Inc. (ALNY) reported a significant financial turnaround for the nine months ended September 30, 2025, achieving a net income of $127.3
• Alnylam's Q2 Revenue Soars 60% on Strong Product & Collaboration Growth — Jul 31, 2025 Risk: medium
  Alnylam Pharmaceuticals reported a significant increase in total revenue for the three and six months ended June 30, 2025. Total revenue for the second quarter
• Alnylam Pharmaceuticals Q1 2025 Update — May 1, 2025 Risk: medium
  Alnylam Pharmaceuticals, Inc. filed its quarterly report for the period ending March 31, 2025. The filing details financial performance and business operations
• Alnylam Pharmaceuticals Q3 2024 Update — Oct 31, 2024 Risk: medium
  Alnylam Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance, including product and collabora
• Alnylam Pharmaceuticals Q2 2024 10-Q Filing — Aug 1, 2024 Risk: medium
  Alnylam Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance, including product and collaboration
• Alnylam Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — May 2, 2024 Risk: medium
  ALNYLAM PHARMACEUTICALS, INC. (ALNY) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Alnylam Pharmaceuticals reported financial results for the qua

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX